TVM Capital closes $150-million life sciences fund

Guest Contributor
June 4, 2012

TVM Capital has closed a $150-million venture fund focused on early-stage drug development and life sciences firms. Investment in TVM Life Science Ventures VII is led by Teralys Capital with $65 million. Other investors in the Montreal-based fund include Eli Lilly & Co, BDC Venture Capital, Fondaction and Advantus Capital Management, a subsidiary of the Minne-sota Life Insurance Co. As part of its participation, Eli Lilly will establish a Canadian unit of Chorus, its global, early-stage drug development network providing expertise and advice up to proof-of-concept....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.